File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Serum adiponectin is reduced in acromegaly and normalized after correction of growth hormone excess

TitleSerum adiponectin is reduced in acromegaly and normalized after correction of growth hormone excess
Authors
Issue Date2004
PublisherThe Endocrine Society. The Journal's web site is located at http://jcem.endojournals.org
Citation
Journal Of Clinical Endocrinology And Metabolism, 2004, v. 89 n. 11, p. 5448-5453 How to Cite?
AbstractAdiponectin, an adipocyte-derived hormone, possesses insulin-sensitizing, antiinflammatory, and antiatherogenic properties. We hypothesized that hypoadiponectinemia was present in acromegaly, as in other conditions with increased insulin resistance and cardiovascular risk. Using an in-house RIA, serum adiponectin was determined in 35 patients with active acromegaly and 35 age-, sex-, and body mass index-matched healthy controls. Twenty-five patients were restudied after GH-lowering therapies. Serum adiponectin was significantly reduced in the acromegalic patients (4.3 ± 1.8 vs. 6.7 ± 1.8 μg/ml in controls; P < 0.001), but was increased after treatment with Sandostatin LAR, a long-acting somatostatin analog (5.8 ± 2.6 vs. 3.8 ± 1.6 μg/ml pretreatment; P < 0.001; n = 15) or transsphenoidal surgery (6.5 ± 2.7 vs. 3.9 ± 1.5 μg/ml preoperation; P < 0.01; n = 10). Fasting insulin was an independent determinant of serum adiponectin levels (P < 0.01) in control subjects, contributing to 11.7% of the variance in circulating adiponectin. In cultured 3T3-L1 adipocytes, adiponectin mRNA levels were decreased by insulin (1.5 μM; P < 0.005) or IGF-I (1 μg/ml; P < 0.05), but not by GH (1 μM) or somatostatin (1 μM). In conclusion, hypoadiponectinemia is present in active acromegaly, probably secondary to the inhibitory effect of high circulating insulin levels. Hypoadiponectinemia, reversible with GH-lowering therapies, may contribute to the increased insulin resistance and cardiovascular risk in patients with acromegaly.
Persistent Identifierhttp://hdl.handle.net/10722/78133
ISSN
2015 Impact Factor: 5.531
2015 SCImago Journal Rankings: 2.940
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLam, KSLen_HK
dc.contributor.authorXu, Aen_HK
dc.contributor.authorTan, KCBen_HK
dc.contributor.authorWong, LCen_HK
dc.contributor.authorTiu, SCen_HK
dc.contributor.authorTam, Sen_HK
dc.date.accessioned2010-09-06T07:39:32Z-
dc.date.available2010-09-06T07:39:32Z-
dc.date.issued2004en_HK
dc.identifier.citationJournal Of Clinical Endocrinology And Metabolism, 2004, v. 89 n. 11, p. 5448-5453en_HK
dc.identifier.issn0021-972Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/78133-
dc.description.abstractAdiponectin, an adipocyte-derived hormone, possesses insulin-sensitizing, antiinflammatory, and antiatherogenic properties. We hypothesized that hypoadiponectinemia was present in acromegaly, as in other conditions with increased insulin resistance and cardiovascular risk. Using an in-house RIA, serum adiponectin was determined in 35 patients with active acromegaly and 35 age-, sex-, and body mass index-matched healthy controls. Twenty-five patients were restudied after GH-lowering therapies. Serum adiponectin was significantly reduced in the acromegalic patients (4.3 ± 1.8 vs. 6.7 ± 1.8 μg/ml in controls; P < 0.001), but was increased after treatment with Sandostatin LAR, a long-acting somatostatin analog (5.8 ± 2.6 vs. 3.8 ± 1.6 μg/ml pretreatment; P < 0.001; n = 15) or transsphenoidal surgery (6.5 ± 2.7 vs. 3.9 ± 1.5 μg/ml preoperation; P < 0.01; n = 10). Fasting insulin was an independent determinant of serum adiponectin levels (P < 0.01) in control subjects, contributing to 11.7% of the variance in circulating adiponectin. In cultured 3T3-L1 adipocytes, adiponectin mRNA levels were decreased by insulin (1.5 μM; P < 0.005) or IGF-I (1 μg/ml; P < 0.05), but not by GH (1 μM) or somatostatin (1 μM). In conclusion, hypoadiponectinemia is present in active acromegaly, probably secondary to the inhibitory effect of high circulating insulin levels. Hypoadiponectinemia, reversible with GH-lowering therapies, may contribute to the increased insulin resistance and cardiovascular risk in patients with acromegaly.en_HK
dc.languageengen_HK
dc.publisherThe Endocrine Society. The Journal's web site is located at http://jcem.endojournals.orgen_HK
dc.relation.ispartofJournal of Clinical Endocrinology and Metabolismen_HK
dc.rightsJournal of Clinical Endocrinology and Metabolism. Copyright © The Endocrine Society.en_HK
dc.subject.mesh3T3-L1 Cellsen_HK
dc.subject.meshAcromegaly - blooden_HK
dc.subject.meshAdiponectinen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAnimalsen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHuman Growth Hormone - secretionen_HK
dc.subject.meshHumansen_HK
dc.subject.meshInsulin - blooden_HK
dc.subject.meshIntercellular Signaling Peptides and Proteins - blooden_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiceen_HK
dc.subject.meshMiddle Ageden_HK
dc.titleSerum adiponectin is reduced in acromegaly and normalized after correction of growth hormone excessen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0021-972X&volume=89&issue=11&spage=5448&epage=53&date=2004&atitle=Serum+adiponectin+is+reduced+in+acromegaly+and+normalized+after+correction+of+growth+hormone+excessen_HK
dc.identifier.emailLam, KSL:ksllam@hku.hken_HK
dc.identifier.emailXu, A:amxu@hkucc.hku.hken_HK
dc.identifier.emailTan, KCB:kcbtan@hku.hken_HK
dc.identifier.authorityLam, KSL=rp00343en_HK
dc.identifier.authorityXu, A=rp00485en_HK
dc.identifier.authorityTan, KCB=rp00402en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1210/jc.2003-032023en_HK
dc.identifier.pmid15531496-
dc.identifier.scopuseid_2-s2.0-8744234072en_HK
dc.identifier.hkuros108704en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-8744234072&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume89en_HK
dc.identifier.issue11en_HK
dc.identifier.spage5448en_HK
dc.identifier.epage5453en_HK
dc.identifier.isiWOS:000224946300027-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLam, KSL=8082870600en_HK
dc.identifier.scopusauthoridXu, A=7202655409en_HK
dc.identifier.scopusauthoridTan, KCB=8082703100en_HK
dc.identifier.scopusauthoridWong, LC=25123484000en_HK
dc.identifier.scopusauthoridTiu, SC=7003310747en_HK
dc.identifier.scopusauthoridTam, S=7202037323en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats